Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild to Moderate Asthma Clear all
Completed Phase 3 Interventional Results available

Use of Dexamethasone in Pediatric Asthma Exacerbations

NCT02192827
View directory record Official record
Conditions
Asthma
Interventions
Dexamethasone Sodium Phosphate Injection
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
2 Years to 20 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma

NCT03364608
View directory record Official record
Conditions
Asthma
Interventions
AS MDI 90 μg, AS MDI 180 µg, Placebo MDI, Proventil 90 μg, Proventil 180 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Rolling Hills Estates, California • Stockton, California • Winter Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044824
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 4 Interventional

Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma

NCT01241006
View directory record Official record
Conditions
Asthma, Reactive Airway Disease
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
Alameda County Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics

NCT02382510
View directory record Official record
Conditions
Asthma
Interventions
TRN-157, Placebo, Tiotropium
Drug · Other
Lead sponsor
Theron Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Costa Mesa, California • Gold River, California • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Not applicable Interventional

Asthma In-Home Monitoring (AIM) Trial

NCT00282516
View directory record Official record
Conditions
Mild, Moderate and Severe Persistent Asthma as Defined by NHLBI-2 Guidelines
Interventions
In-home telemonitoring of pediatric patients with persistent asthma
Procedure
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
6 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Tripler AMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

NCT00995904
View directory record Official record
Conditions
Asthma
Interventions
84ug MAP0020, 42ug MAP0020, 21ug MAP0020
Drug
Lead sponsor
Allergan
Industry
Eligibility
4 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Cypress, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Pharmacokinetics of QAW039

NCT01253603
View directory record Official record
Conditions
Persistent Asthma
Interventions
QAW039 capsules once daily for 28 days, Placebo to QAW039 capsules once daily for 28 days, Fluticasone propionate inhaler twice daily for 28 days
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma

NCT01103037
View directory record Official record
Conditions
Asthma
Interventions
QAV680, QAV680 Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Cypress, California • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

NCT00044811
View directory record Official record
Conditions
Asthma
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 22, 2026, 6:54 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

NCT07660731
View directory record Official record
Conditions
Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
Interventions
PF-08103402, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

NCT02105012
View directory record Official record
Conditions
Asthma
Interventions
BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg, BD MDI 40 µg, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
41
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation

NCT01581177
View directory record Official record
Conditions
Asthma
Interventions
Albuterol DPI 25 mcg/inh, Albuterol DPI 90 mcg/inh, Placebo DPI, Albuterol MDI 90 mcg/inh
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

NCT03371459
View directory record Official record
Conditions
Asthma
Interventions
AS MDI, Proventil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Winter Park, Florida • North Dartmouth, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

NCT01641081
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jul 22, 2026, 6:54 PM EDT
Completed No phase listed Observational

Patterns of Neurocircuitry Activation In Severe Asthma

NCT03230188
View directory record Official record
Conditions
Lung Diseases
Interventions
functional Magnetic Resonance Imaging (research grade), Cognitive Function Testing (non-diagnostic), Asthma and Psychological Questionnaires (non-diagnostic)
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

NCT01370317
View directory record Official record
Conditions
Asthma
Interventions
MK-1029, Placebo for MK-1029
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Costa Mesa, California • Rolling Hills Estates, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma

NCT02104674
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Montelukast, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 6:54 PM EDT
Recruiting Phase 1 Interventional

A Study of CDX-622 in Participants With Mild to Moderate Asthma

NCT07330778
View directory record Official record
Conditions
Mild to Moderate Asthma
Interventions
CDX-622
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
San Francisco, California • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 6:54 PM EDT
Terminated No phase listed Observational

Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics

NCT01698983
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Jeanette Marketon, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jul 22, 2026, 6:54 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 3 Interventional

A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects

NCT00449501
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/formoterol pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
46
States / cities
Muscle Shoals, Alabama • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2011 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation

NCT02210806
View directory record Official record
Conditions
Asthma
Interventions
A006 DPI, Placebo DPI, Proventil® MDI
Drug · Other
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
San Jose, California • Medford, Oregon • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Jul 22, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma

NCT02322775
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
17
States / cities
Los Angeles, California • Rolling Hills Estates, California • Clearwater, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Jul 22, 2026, 6:54 PM EDT